Former Chief Medical Officer · Zentalis Pharmaceuticals, Inc. (ZNTL)

Diana Hausman

FY2024 is the first fiscal year CompBrief holds for Diana Hausman as a named executive officer of Zentalis Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$7,063,793

Salary $295,577Stock awards $3,945,375Bonus $75,000

3rd of 6 named executive officers at Zentalis Pharmaceuticals by FY2024 total.

6 named officers on file for Zentalis Pharmaceuticals, FY2024

Diana Hausman’s pay file — $29

  • 1 fiscal year of pay, line by line
  • ZNTL’s disclosed peer group of 23 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Zentalis Pharmaceuticals’s whole pay program stands against its peers

  • Zentalis Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ZNTL→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2025 (DEF 14A).

Free

Get Diana Hausman’s full pay file as a PDF — free

More than this page: up to 10 years of Diana’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Diana Hausman compensation by year

Zentalis Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as Zentalis Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$295,577
Bonus$75,000
Stock awards$3,945,375
Option awards$2,716,337
Non-equity incentive$0
Pension and deferred compensation$0
All other$31,504
Total$7,063,793

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Zentalis Pharmaceuticals, Inc. DEF 14A filed April 30, 2025, accession 0001725160-25-000092, and prior-year filings.

How this page was built: the Zentalis Pharmaceuticals, Inc. filed document, accession 0001725160-25-000092. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2025.

Zentalis Pharmaceuticals’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Julie EastlandPresident and Chief Executive Officer$8,188,909
Kimberly BlackwellFormer Chief Executive Officer and Interim Chief Medical Officer$7,466,453
Diana Hausman · this pageFormer Chief Medical Officer$7,063,793
Cam GallagherFormer President, Interim Chief Financial Officer and Interim Treasurer$5,819,024
Mark LacknerFormer Chief Scientific Officer$4,788,822
Andrea PaulFormer Chief Legal Officer and Corporate Secretary$3,678,975

Board service

Zentalis Pharmaceuticals board · FY2023
Director compensation in US dollars, as Zentalis Pharmaceuticals reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2023$38,442$868,542——$906,984

Each year as the company reported it in Zentalis Pharmaceuticals's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Zentalis Pharmaceuticals pays directors a $45,000 cash retainer and $425,000 in RSUs. As stated in Zentalis Pharmaceuticals's FY2023 proxy.

The full Zentalis Pharmaceuticals compensation record

free company brief

This page is one person within Zentalis Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Zentalis Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Zentalis Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Diana Hausman's compensation dossier · One-time report. No refunds.